METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Clinical trials for METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a radioactive drug called lutetium Lu 177 dotatate in 30 people with a rare and aggressive form of prostate cancer that has spread. The drug seeks out and delivers radiation directly to cancer cells that have certain markers. The goal is to see if it can shrink t…
Matched conditions: METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New scan spots prostate cancer that standard tests miss
Diagnosis Recruiting nowThis study tests whether a special PET scan using 18F-fluciclovine can better detect advanced prostate cancer that doesn't show up well on standard PSMA scans. About 30 people with metastatic prostate cancer that has low PSMA levels or neuroendocrine features will get the scan an…
Matched conditions: METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated May 18, 2026 12:02 UTC